Clinical Trials Logo

Hyperglycemia clinical trials

View clinical trials related to Hyperglycemia.

Filter by:

NCT ID: NCT00029250 Withdrawn - HIV Infections Clinical Trials

Garlic in Hyperlipidemia Caused by HAART

Start date: November 2001
Phase: Phase 2
Study type: Interventional

The purpose of this study is to test the effectiveness and tolerability of garlic pills in lowering cholesterol and triglycerides in hyperlipidemic HIV-infected individuals who are being treated with highly active antiretroviral therapy (HAART).

NCT ID: NCT00005889 Recruiting - Hyperglycemia Clinical Trials

Gluconeogenesis in Very Low Birth Weight Infants Who Are Receiving Nutrition By Intravenous Infusion

Start date: October 1999
Phase: N/A
Study type: Interventional

RATIONALE: Very low birth weight infants have problems maintaining normal blood sugar levels. Gluconeogenesis is the production of sugar from amino acids and fats. The best combination of amino acids, fat, and sugar to help very low birth weigh infants maintain normal blood sugar levels is not yet known. PURPOSE: Clinical trial to study how very low birth weight infants break down amino acids, fat, and sugar given by intravenous infusion, and the effect of different combinations of nutrients on the infants' ability to maintain normal blood sugar levels.

NCT ID: NCT00004419 Completed - Insulin Resistance Clinical Trials

Study of Recombinant Human Insulin-Like Growth Factor I in Patients With Severe Insulin Resistance

Start date: April 1998
Phase: N/A
Study type: Interventional

OBJECTIVES: I. Determine the efficacy and toxic effects of recombinant human insulin-like growth factor I (rhIGF-I) on carbohydrate tolerance, insulin action, insulin secretion, hyperandrogenism, and hyperlipidemia in patients with severe insulin resistance who have failed other therapies. II. Determine the dose and time response of rhIGF-I on carbohydrate homeostasis and secondary abnormalities in this patient population. III. Determine the effect of rhIGF-I on insulin clearance, the regulation of insulin-like growth factor binding protein 1, the regulation of sex hormone binding globulin, and hypothalamic pituitary gonadal axis in this patient population.